nuShores Biosciences

ABOUT US:

NuShores Biosciences, LLC, founded in 2014, was established to commercialize innovative bone and tissue regeneration technologies developed at the University of Arkansas at Little Rock. We aim to enhance quality of life and profitably compete in the bone-substitute industry by providing improved bone and tissue regeneration solutions, reducing healthcare costs, treatment risks, and healing times.

ABOUT NUCRESS™ BONE VOID FILLER

The NuCress™ bone void filler product is manufactured as a solid 3D structure - A highly porous scaffold offered in a 2 cc block that can be easily adjusted to the desired shape/size in the OR with simple surgical equipment such as scissors or scalpels. NuCress™ bone void filler is highly hydrophilic with high liquid uptake characteristics, which results in excellent blood uptake and tissue integration.

INTELLIGENT FACTORY IN A BOX VISION

PRODUCTION, SCALE-UP, AND FOUNDATION FOR FUTURE DISTRIBUTED MEDICAL MANUFACTURING INNOVATIONS

01 FULLY AUTOMATED PRODUCTION SYSTEM

Moving from a highly manual, highly variable process to an automated error-free solution for 3D bone filler scaffolds or other tissue scaffolds

02 PREDICTIVE QUALITY REPORTING

Predictive Quality Analytics through Artificial Intelligence (AI) and Machine Learning

03 REAL-TIME QUALITY MONITORING

Real-time data on system performance allows any errors to be spotted and corrected immediately, while data can be analyzed in real time to deliver situational awareness - a system view of overall performance which helps to identify new opportunities for refinement or improvement such as shorter process times, reduced material waste and improved device quality.

04 PACKAGING AND LABELING

Incorporating Intelligent packaging technologies for a final customer facing product.

05 STERILIZATION

Integrating patent-pending, automated and environmentally safe approaches for the packaged and labeled products.

JOIN OUR TEAM
nushores.com/careers

2016

GEN 1 MFG

HIGHLY MANUAL AND VARIABLE PROCESS



NUCRESS™ BVF AS CURRENTLY PRODUCED

2024

GEN 1+: ISLANDS OF AUTOMATION



INCORPORATING AUTOMATED PROCESSES LEARNED FROM FIAB INNOVATIONS INTO CURRENT MANUFACTURING PRACTICES

RESULTING IN REDUCED PRODUCT VARIABILITY AND WASTE

2026

GEN 2+ FIAB



Current FIAB Prototype

TRANSITION TO FULLY AUTOMATED MANUFACTURING PROCESS



WHILE WORKING TOWARDS MINIATURIZATION

2028

GEN 3+ AND BEYOND



FLEXIBLE, TUNABLE MANUFACTURING DEPLOYABLE IN MULTIPLE POINTS OF CARE

TO REGENERATE ONE OR MULTIPLE TISSUES WITH CARTDRIDGE-LIKE RAW MATERIAL ADJUSTMENT



2030

GLP, QMS, CGMP
ORTHOPEDIC, SPINE, DENTAL INDICATIONS

GLP, QMS, CGMP
BONE, NERVE, VEINS, MULTI-TISSUE ETC

"We are anticipating **the pace** of innovation to bring it to use **today**, and be future-proof **tomorrow**"

Sharon Ballard, CEO

TechConnect INNOVATION AWARD 2019

TechConnect DEFENSE INNOVATION AWARD 2018

MADE POSSIBLE BY:
MTEC
Medical Technology Enterprise Consortium

CONTACT US
(866)-NUCRESS
nushores.com
info@nushores.com

These results have not yet been evaluated by the Food and Drug Administration.
The NuCress™ scaffold is not yet FDA cleared and is not available for sale at this time.